Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and ...
Novo Nordisk A/S is planning a large study of its next-generation obesity shot CagriSema in children, a sign the drugmaker is ...
Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...
Shortly after, Novo Nordisk's CEO Mike Doustdar signaled the company is "all in" on the forthcoming launch of oral semaglutide, emphasizing robust supply readiness ahead of the anticipated year-end ...
A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...
After falling short in adults, Novo Nordisk pivots CagriSema into a sweeping global trial targeting childhood obesity.
Lilly's next-generation obesity shot is starting to look like the company's most powerful swing yet in a market investors expect to reshape global healthcare economics. After releasing late-stage data ...
Ozempic has been approved for type-2 diabetes, while Novo Nordisk’s other global blockbuster Wegovy is targeted at obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback